Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.

Hu Z, Hatano H, Hammond SP, Smith D, Wild M, Gupta S, Whitcomb J, Kalayjian RC, Gripshover B, Kuritzkes DR.

J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):494-500.

PMID:
17496561
2.

The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.

Miller V, Stürmer M, Staszewski S, Gröschel B, Hertogs K, de Béthune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA.

AIDS. 1998 May 7;12(7):705-12.

PMID:
9619801
3.

Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.

Kagan RM, Lee TS, Ross L, Lloyd RM Jr, Lewinski MA, Potts SJ.

Antiviral Res. 2007 Sep;75(3):210-8. Epub 2007 Apr 4.

PMID:
17442410
4.

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G, Tisdale M.

AIDS. 2000 Jan 28;14(2):163-71.

PMID:
10708287
5.

Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.

Bradshaw D, Malik S, Booth C, Van Houtte M, Pattery T, Waters A, Ainsworth J, Geretti AM.

Antimicrob Agents Chemother. 2007 Dec;51(12):4489-91. Epub 2007 Sep 17.

6.
7.
8.

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.

Svarovskaia ES, Margot NA, Bae AS, Waters JM, Goodman D, Zhong L, Borroto-Esoda K, Miller MD.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):174-80.

PMID:
17667333
9.

Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.

Llibre JM, Bonjoch A, Iribarren J, Galindo MJ, Negredo E, Domingo P, Pérez-Alvarez N, Martinez-Picado J, Schapiro J, Clotet B; HIV Conference Call Study Group.

HIV Med. 2008 Aug;9(7):508-13. doi: 10.1111/j.1468-1293.2008.00581.x. Epub 2008 May 15. Erratum in: HIV Med. 2009 Jul;10(6):396.

10.

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

Margot NA, Waters JM, Miller MD.

Antimicrob Agents Chemother. 2006 Dec;50(12):4087-95. Epub 2006 Sep 18.

12.

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.

Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M.

AIDS. 1998 Jun 18;12(9):1015-20.

PMID:
9662197
13.

Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.

Feng JY, Myrick FT, Margot NA, Mulamba GB, Rimsky L, Borroto-Esoda K, Selmi B, Canard B.

Nucleosides Nucleotides Nucleic Acids. 2006;25(1):89-107.

PMID:
16440988
14.

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.

Winston A, Mandalia S, Pillay D, Gazzard B, Pozniak A.

AIDS. 2002 Oct 18;16(15):2087-9.

PMID:
12370512
15.

Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.

Descamps D, Ait-Khaled M, Craig C, Delarue S, Damond F, Collin G, Brun-Vézinet F.

Antivir Ther. 2006;11(6):701-5.

PMID:
17310814
16.
17.

Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.

Delaugerre C, Roudiere L, Peytavin G, Rouzioux C, Viard JP, Chaix ML.

J Clin Virol. 2005 Mar;32(3):241-4.

PMID:
15722030
19.
20.

The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.

Svarovskaia ES, Feng JY, Margot NA, Myrick F, Goodman D, Ly JK, White KL, Kutty N, Wang R, Borroto-Esoda K, Miller MD.

J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):428-36. doi: 10.1097/QAI.0b013e31817bbe93.

PMID:
18614922

Supplemental Content

Support Center